Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy

NCT ID: NCT02909049

Last Updated: 2018-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2018-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the effectiveness of two anesthetic techniques by measuring the pain through visual analog scale (VAS), to obtain saturation prostate biopsies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the effectiveness of two anesthetic techniques by measuring the pain through visual analog scale (VAS), to obtain saturation prostate biopsies.

Anesthetic technique (control) - Intravenous sedation with Midazolam, Fentanile and Ketamine.

Anesthetic technique (intervention) - Regional Mepivacaine infiltration of periprostatic region.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CONTROL

Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy

Group Type ACTIVE_COMPARATOR

MIDAZOLAM

Intervention Type DRUG

Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.

FENTANILE

Intervention Type DRUG

Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.

KETAMINE

Intervention Type DRUG

Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.

EXPERIMENTAL

Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.

Group Type EXPERIMENTAL

MEPIVACAÍNE

Intervention Type DRUG

Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MIDAZOLAM

Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.

Intervention Type DRUG

MEPIVACAÍNE

Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.

Intervention Type DRUG

FENTANILE

Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.

Intervention Type DRUG

KETAMINE

Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MIDAZOLAM 15mg/3ml ATC N05CD08 MAN 65319 MEPIVACAINE 2% ATC N01BB03 MAN 62606 FENTANILE 0,05 mg/ml ATC N01AH01 MAN 41764 KETAMINE 50 mg/ml ATC N01AX03 Marketing Authorisation number 47034

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male patient
* Persistence of suspected prostate cancer by altering the prostatic specific antigen and / or digital rectal examination.
* Two previous negative prostate biopsies .
* Age \< 75 years.
* Signature of informed consent to perform prostate biopsy.
* Signature of informed consent for the study.

Exclusion Criteria

* Age \> 75 years.
* Absence of consent or refusal to the study .
* Presence of prostate cancer in previous biopsy observation .
* Medical-surgical patient's problems, absolutely contraindicating biopsy under local anesthesia.
* Presence of any allergies to medications involved in the study .
* Patient's clinical situation that does not allow an outpatient operation and aftercare required .
* Medical condition of the patient, preventing the realization of outpatient biopsy.
* No companion.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Complexo Hospitalario Universitario de A Coruña

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

José Luis Ponce Díaz-Reixa

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jose L Ponce, MD

Role: PRINCIPAL_INVESTIGATOR

Complejo Hospitalario Universitario, A Coruña

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jose Luis Ponce Diaz-Reixa

A Coruña, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

URO - CHUAC - BPSat - 001.

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.